Abstract
The knowledge on systemic autoinflammatory disorders (SAID) is expanding rapidly and new signalling pathways are being decrypted. The concept of autoinflammation has been proposed since 1999, to define a group of diseases with abnormal innate immunity activation. Since then, more than 30 monogenic SAID have been described. In this review, we first describe inflammasomopathies and SAID related to the interleukin-1 pathway. Recent insights into the pathogenesis of familial Mediterranean fever and the function of Pyrin are detailed. In addition, complex or polygenic SAID, such as Still’s disease or PFAPA syndrome, are also discussed. Then, major players driving autoinflammation, such as type-1 interferonopathies (including the recently described haploinsuffiency in A20 and otulipenia), TNF-associated periodic syndromes, defects in ubiquitination, and SAID with overlapping features of autoimmunity or immunodeficiency. Discoveries of the pathogenic role of mosaicism, intronic defects coupled to the likelihood to identify digenic or polygenic diseases are providing new challenges for physicians and geneticists. This comprehensive review depicts the various SAID, presenting them according to their predominant pathophysiological mechanism, with a particular emphasis on recent findings. Epidemiologic data are also presented. Finally, we propose a practical diagnostic approach to the most common monogenic SAID, based on the most characteristic clinical presentation of these disorders.
Similar content being viewed by others
References
French FMF Consortium (1997) A candidate gene for familial Mediterranean fever. Nat Genet 17:25–31. doi:10.1038/ng0997-25
The International FMF Consortium (1997) Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90:797–807
Xu H, Yang J, Gao W, Li L, Li P, Zhang L et al (2014) Innate immune sensing of bacterial modifications of Rho GTPases by the pyrin inflammasome. Nature 513:237–241. doi:10.1038/nature13449
McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M et al (1999) Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97:133–144
Masters SL, Simon A, Aksentijevich I, Kastner DL (2009) Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu rev Immunol 27:621–668. doi:10.1146/annurev.immunol.25.022106.141627
Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237–241. doi:10.1038/nature04516
McGonagle D, McDermott MF (2006) A proposed classification of the immunological diseases. PLoS med 3:e297. doi:10.1371/journal.pmed.0030297
Peckham D, Scambler T, Savic S, McDermott MF (2017) The burgeoning field of innate immune-mediated disease and autoinflammation. J Pathol 241:123–139. doi:10.1002/path.4812
Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519–550. doi:10.1146/annurev.immunol.021908.132612
Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10:417–426
Heller H, Sohar E, Pras M (1961) Ethnic distribution and amyloidosis in familial Mediterranean fever (FMF). Pathol Microbiol (Basel) 24:718–723
Cakır N, Pamuk ÖN, Derviş E, Imeryüz N, Uslu H, Benian Ö et al (2012) The prevalences of some rheumatic diseases in western Turkey: Havsa study. Rheumatol Int 32:895–908. doi:10.1007/s00296-010-1699-4
Kisacik B, Yildirim B, Tasliyurt T, Ozyurt H, Ozyurt B, Yuce S et al (2009) Increased frequency of familial Mediterranean fever in northern Turkey: a population-based study. Rheumatol Int 29:1307–1309. doi:10.1007/s00296-009-0849-z
Sarkisian T, Ajrapetian H, Beglarian A, Shahsuvarian G, Egiazarian A (2008) Familial Mediterranean fever in Armenian population. Georgian Med News 156:105–111
Samuels J, Aksentijevich I, Torosyan Y, Centola M, Deng Z, Sood R et al (1998) Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine (Baltimore) 77:268–297
Deltas CC, Mean R, Rossou E, Costi C, Koupepidou P, Hadjiyanni I et al (2002) Familial Mediterranean fever (FMF) mutations occur frequently in the Greek-Cypriot population of Cyprus. Genet Test 6:15–21. doi:10.1089/109065702760093861
La Regina M, Nucera G, Diaco M, Procopio A, Gasbarrini G, Notarnicola C et al (2003) Familial Mediterranean fever is no longer a rare disease in Italy. Eur J hum Genet EJHG 11:50–56. doi:10.1038/sj.ejhg.5200916
Toplak N, Dolezalovà P, Constantin T, Sedivà A, Pašić S, Cižnar P et al (2010) Periodic fever syndromes in eastern and central European countries: results of a pediatric multinational survey. Pediatr Rheumatol Online J 8:29. doi:10.1186/1546-0096-8-29
Migita K, Izumi Y, Jiuchi Y, Iwanaga N, Kawahara C, Agematsu K et al (2016) Familial Mediterranean fever is no longer a rare disease in Japan. Arthritis res Ther 18:175. doi:10.1186/s13075-016-1071-5
Sohar E, Gafni J, Pras M, Heller H (1967) Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J med 43:227–253
Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T et al (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40:1879–1885. doi:10.1002/1529-0131(199710)40:10<1879::AID-ART23>3.0.CO;2-M
Berkun Y, Eisenstein EM (2014) Diagnostic criteria of familial Mediterranean fever. Autoimmun Rev 13:388–390. doi:10.1016/j.autrev.2014.01.045
Federici S, Sormani MP, Ozen S, Lachmann HJ, Amaryan G, Woo P et al (2015) Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Ann Rheum Dis 74:799–805. doi:10.1136/annrheumdis-2014-206580
Chae JJ, Cho Y-H, Lee G-S, Cheng J, Liu PP, Feigenbaum L et al (2011) Gain-of-function pyrin mutations induce NLRP3 protein-independent interleukin-1β activation and severe autoinflammation in mice. Immunity 34:755–768. doi:10.1016/j.immuni.2011.02.020
Booty MG, Chae JJ, Masters SL, Remmers EF, Barham B, Le JM et al (2009) Familial Mediterranean fever with a single MEFV mutation: where is the second hit? Arthritis Rheum 60:1851–1861. doi:10.1002/art.24569
Touitou I (2001) The spectrum of familial Mediterranean fever (FMF) mutations. Eur J hum Genet EJHG 9:473–483. doi:10.1038/sj.ejhg.5200658
Tchernitchko DO, Gérard-Blanluet M, Legendre M, Cazeneuve C, Grateau G, Amselem S (2006) Intrafamilial segregation analysis of the p.E148Q MEFV allele in familial Mediterranean fever. Ann Rheum Dis 65:1154–1157. doi:10.1136/ard.2005.048124
Chae JJ, Komarow HD, Cheng J, Wood G, Raben N, Liu PP et al (2003) Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell 11:591–604
Federici S, Calcagno G, Finetti M, Gallizzi R, Meini A, Vitale A et al (2012) Clinical impact of MEFV mutations in children with periodic fever in a prevalent western European Caucasian population. Ann Rheum dis 71:1961–1965. doi:10.1136/annrheumdis-2011-200977
Omenetti A, Carta S, Delfino L, Martini A, Gattorno M, Rubartelli A (2014) Increased NLRP3-dependent interleukin 1β secretion in patients with familial Mediterranean fever: correlation with MEFV genotype. Ann Rheum Dis 73:462–469. doi:10.1136/annrheumdis-2012-202774
Park YH, Wood G, Kastner DL, Chae JJ (2016) Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol 17:914–921. doi:10.1038/ni.3457
Chae JJ, Wood G, Masters SL, Richard K, Park G, Smith BJ et al (2006) The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S a 103:9982–9987. doi:10.1073/pnas.0602081103
Masters SL, Lagou V, Jéru I, Baker PJ, Van Eyck L, Parry DA et al (2016) Familial autoinflammation with neutrophilic dermatosis reveals a regulatory mechanism of pyrin activation. Sci Transl med 8:332ra45. doi:10.1126/scitranslmed.aaf1471
Van Gorp H, Saavedra PHV, de Vasconcelos NM, Van Opdenbosch N, Vande Walle L, Matusiak M et al (2016) Familial Mediterranean fever mutations lift the obligatory requirement for microtubules in pyrin inflammasome activation. Proc Natl Acad Sci U S A 113:14384–14389. doi:10.1073/pnas.1613156113
Kim ML, Chae JJ, Park YH, De Nardo D, Stirzaker RA, Ko H-J et al (2015) Aberrant actin depolymerization triggers the pyrin inflammasome and autoinflammatory disease that is dependent on IL-18, not IL-1β. J Exp Med 212:927–938. doi:10.1084/jem.20142384
Gao W, Yang J, Liu W, Wang Y, Shao F (2016) Site-specific phosphorylation and microtubule dynamics control pyrin inflammasome activation. Proc Natl Acad Sci U S a 113:E4857–E4866. doi:10.1073/pnas.1601700113
Chung LK, Park YH, Zheng Y, Brodsky IE, Hearing P, Kastner DL et al (2016) The Yersinia virulence factor YopM hijacks host kinases to inhibit type III effector-triggered activation of the pyrin inflammasome. Cell Host Microbe 20:296–306. doi:10.1016/j.chom.2016.07.018
Ratner D, Orning MPA, Proulx MK, Wang D, Gavrilin MA, Wewers MD et al (2016) The Yersinia pestis effector YopM inhibits pyrin inflammasome activation. PLoS Pathog 12:e1006035. doi:10.1371/journal.ppat.1006035
Schaner P, Richards N, Wadhwa A, Aksentijevich I, Kastner D, Tucker P et al (2001) Episodic evolution of pyrin in primates: human mutations recapitulate ancestral amino acid states. Nat Genet 27:318–321. doi:10.1038/85893
Houten SM, Kuis W, Duran M, de Koning TJ, van Royen-Kerkhof A, Romeijn GJ et al (1999) Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet 22:175–177. doi:10.1038/9691
Gershoni-Baruch R, Brik R, Zacks N, Shinawi M, Lidar M, Livneh A (2003) The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum 48:1149–1155. doi:10.1002/art.10944
Vuch J, Marcuzzi A, Bianco AM, Tommasini A, Zanin V, Crovella S (2013) Evolutionary hypothesis of the mevalonate kinase deficiency. Med Hypotheses 80:67–69. doi:10.1016/j.mehy.2012.10.016
van der Hilst JCH, Bodar EJ, Barron KS, Frenkel J, Drenth JPH, van der Meer JWM et al (2008) Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) 87:301–310. doi:10.1097/MD.0b013e318190cfb7
Zhang S (2016) Natural history of mevalonate kinase deficiency: a literature review. Pediatr Rheumatol Online J 14:30. doi:10.1186/s12969-016-0091-7
Lainka E, Neudorf U, Lohse P, Timmann C, Bielak M, Stojanov S et al (2012) Incidence and clinical features of hyperimmunoglobulinemia D and periodic fever syndrome (HIDS) and spectrum of mevalonate kinase (MVK) mutations in German children. Rheumatol Int 32:3253–3260. doi:10.1007/s00296-011-2180-8
Prieur AM, Griscelli C (1983) Nosologic aspects of systemic forms of very early onset juvenile arthritis. Apropos of 17 cases. Ann Pediatr (Paris) 30:565–569
Galeotti C, Georgin-Lavialle S, Sarrabay G, Touitou I, Koné-Paut I (2016) Mevalonate kinase deficiency in 2016. Rev Med Interne. doi:10.1016/j.revmed.2016.08.019
Lindor NM, Arsenault TM, Solomon H, Seidman CE, McEvoy MT (1997) A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc 72:611–615. doi:10.1016/S0025-6196(11)63565-9
Yang H, Reinherz EL (2006) CD2BP1 modulates CD2-dependent T cell activation via linkage to protein tyrosine phosphatase (PTP)-PEST. J Immunol Baltim md 1950 176:5898–5907
Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T (2012) Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)--a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol 66:409–415. doi:10.1016/j.jaad.2010.12.025
Shoham NG, Centola M, Mansfield E, Hull KM, Wood G, Wise CA et al (2003) Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci U S a 100:13501–13506. doi:10.1073/pnas.2135380100
Yu J-W, Fernandes-Alnemri T, Datta P, Wu J, Juliana C, Solorzano L et al (2007) Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants. Mol Cell 28:214–227. doi:10.1016/j.molcel.2007.08.029
Holzinger D, Roth J (2016) Alarming consequences - autoinflammatory disease spectrum due to mutations in proline-serine-threonine phosphatase-interacting protein 1. Curr Opin Rheumatol 28:550–559. doi:10.1097/BOR.0000000000000314
Holzinger D, Fassl SK, de Jager W, Lohse P, Röhrig UF, Gattorno M et al (2015) Single amino acid charge switch defines clinically distinct proline-serine-threonine phosphatase-interacting protein 1 (PSTPIP1)-associated inflammatory diseases. J Allergy Clin Immunol 136:1337–1345. doi:10.1016/j.jaci.2015.04.016
Leuenberger M, Berner J, Di Lucca J, Fischer L, Kaparos N, Conrad C et al (2016) PASS syndrome: an IL-1-driven autoinflammatory disease. Dermatol Basel Switz 232:254–258. doi:10.1159/000443648
Standing ASI, Malinova D, Hong Y, Record J, Moulding D, Blundell MP et al (2017) Autoinflammatory periodic fever, immunodeficiency, and thrombocytopenia (PFIT) caused by mutation in actin-regulatory gene WDR1. J Exp med 214:59–71. doi:10.1084/jem.20161228
Matzinger P (2002) The danger model: a renewed sense of self. Science 296:301–305. doi:10.1126/science.1071059
Bergsbaken T, Fink SL, Cookson BT (2009) Pyroptosis: host cell death and inflammation. Nat rev Microbiol 7:99–109. doi:10.1038/nrmicro2070
Jamilloux Y, Henry T (2013) The inflammasomes: platforms of innate immunity. Médecine Sci MS 29:975–984. doi:10.1051/medsci/20132911013
Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD (2001) Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 29:301–305. doi:10.1038/ng756
Mehr S, Allen R, Boros C, Adib N, Kakakios A, Turner PJ et al (2016) Cryopyrin-associated periodic syndrome in Australian children and adults: epidemiological, clinical and treatment characteristics. J Paediatr Child Health 52:889–895. doi:10.1111/jpc.13270
Cuisset L, Jeru I, Dumont B, Fabre A, Cochet E, Le Bozec J et al (2011) Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France. Ann Rheum Dis 70:495–499. doi:10.1136/ard.2010.138420
Lainka E, Neudorf U, Lohse P, Timmann C, Bielak M, Stojanov S et al (2010) Analysis of cryopyrin-associated periodic syndromes (CAPS) in German children: epidemiological, clinical and genetic characteristics. Klin Padiatr 222:356–361. doi:10.1055/s-0030-1265181
Tanaka N, Izawa K, Saito MK, Sakuma M, Oshima K, Ohara O et al (2011) High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an International Multicenter Collaborative Study. Arthritis Rheum 63:3625–3632. doi:10.1002/art.30512
Levy R, Gérard L, Kuemmerle-Deschner J, Lachmann HJ, Koné-Paut I, Cantarini L et al (2015) Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever registry. Ann Rheum Dis 74:2043–2049. doi:10.1136/annrheumdis-2013-204991
Rowczenio DM, Trojer H, Russell T, Baginska A, Lane T, Stewart NM et al (2013) Clinical characteristics in subjects with NLRP3 V198M diagnosed at a single UK center and a review of the literature. Arthritis res Ther 15:R30. doi:10.1186/ar4171
Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI et al (2006) Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 355:581–592. doi:10.1056/NEJMoa055137
Goldbach-Mansky R (2009) Blocking interleukin-1 in rheumatic diseases. Ann N Y Acad Sci 1182:111–123. doi:10.1111/j.1749-6632.2009.05159.x
Tschopp J, Schroder K (2010) NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 10:210–215. doi:10.1038/nri2725
Martinon F, Mayor A, Tschopp J (2009) The inflammasomes: guardians of the body. Annu rev Immunol 27:229–265. doi:10.1146/annurev.immunol.021908.132715
Pétrilli V, Papin S, Dostert C, Mayor A, Martinon F, Tschopp J (2007) Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 14:1583–1589. doi:10.1038/sj.cdd.4402195
Baroja-Mazo A, Martín-Sánchez F, Gomez AI, Martínez CM, Amores-Iniesta J, Compan V et al (2014) The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat Immunol 15:738–748. doi:10.1038/ni.2919
Hoffman HM, Broderick L (2017) Editorial: it just takes one: somatic mosaicism in autoinflammatory disease. Arthritis Rheumatol Hoboken NJ 69:253–256. doi:10.1002/art.39961
Nakagawa K, Gonzalez-Roca E, Souto A, Kawai T, Umebayashi H, Campistol JM et al (2015) Somatic NLRP3 mosaicism in Muckle-Wells syndrome. A genetic mechanism shared by different phenotypes of cryopyrin-associated periodic syndromes. Ann Rheum Dis 74:603–610. doi:10.1136/annrheumdis-2013-204361
Canna SW, de Jesus AA, Gouni S, Brooks SR, Marrero B, Liu Y et al (2014) An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet 46:1140–1146. doi:10.1038/ng.3089
Romberg N, Al Moussawi K, Nelson-Williams C, Stiegler AL, Loring E, Choi M et al (2014) Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat Genet 46:1135–1139. doi:10.1038/ng.3066
Volker-Touw CML, de Koning HD, Giltay JC, de Kovel CGF, van Kempen TS, Oberndorff KMEJ et al (2017) Erythematous nodes, urticarial rash and arthralgias in a large pedigree with NLRC4-related autoinflammatory disease, expansion of the phenotype. Br J Dermatol 176:244–248. doi:10.1111/bjd.14757
Kitamura A, Sasaki Y, Abe T, Kano H, Yasutomo K (2014) An inherited mutation in NLRC4 causes autoinflammation in human and mice. J Exp Med 211:2385–2396. doi:10.1084/jem.20141091
Kawasaki Y, Oda H, Ito J, Niwa A, Tanaka T, Hijikata A et al (2017) Identification of a high-frequency somatic NLRC4 mutation as a cause of autoinflammation by pluripotent cell-based phenotype dissection. Arthritis Rheumatol Hoboken NJ 69:447–459. doi:10.1002/art.39960
Canna SW, Girard C, Malle L, de Jesus A, Romberg N, Kelsen J et al (2016) Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. J Allergy Clin Immunol. doi:10.1016/j.jaci.2016.10.022
Coers J, Vance RE, Fontana MF, Dietrich WF (2007) Restriction of Legionella pneumophila growth in macrophages requires the concerted action of cytokine and Naip5/Ipaf signalling pathways. Cell Microbiol 9:2344–2357. doi:10.1111/j.1462-5822.2007.00963.x
Yang J, Zhao Y, Shi J, Shao F (2013) Human NAIP and mouse NAIP1 recognize bacterial type III secretion needle protein for inflammasome activation. Proc Natl Acad Sci U S A 110:14408–14413. doi:10.1073/pnas.1306376110
Kortmann J, Brubaker SW, Monack DM (2015) Cutting edge: inflammasome activation in primary human macrophages is dependent on flagellin. J Immunol Baltim md 1950 195:815–819. doi:10.4049/jimmunol.1403100
Raghawan AK, Sripada A, Gopinath G, Pushpanjali P, Kumar Y, Radha V et al (2017) A disease-associated mutant of NLRC4 shows enhanced interaction with SUG1 leading to constitutive FADD-dependent caspase-8 activation and cell death. J Biol Chem 292:1218–1230. doi:10.1074/jbc.M116.763979
Zhong FL, Mamaï O, Sborgi L, Boussofara L, Hopkins R, Robinson K et al (2016) Germline NLRP1 mutations cause skin inflammatory and cancer susceptibility syndromes via inflammasome activation. Cell 167:187–202.e17. doi:10.1016/j.cell.2016.09.001
Soler VJ, Tran-Viet K-N, Galiacy SD, Limviphuvadh V, Klemm TP, St Germain E et al (2013) Whole exome sequencing identifies a mutation for a novel form of corneal intraepithelial dyskeratosis. J Med Genet 50:246–254. doi:10.1136/jmedgenet-2012-101325
Grandemange S, Sanchez E, Louis-Plence P, Tran Mau-Them F, Bessis D, Coubes C et al (2016) A new autoinflammatory and autoimmune syndrome associated with NLRP1 mutations: NAIAD (NLRP1-associated autoinflammation with arthritis and dyskeratosis). Ann Rheum Dis. doi:10.1136/annrheumdis-2016-210021
Masters SL, Gerlic M, Metcalf D, Preston S, Pellegrini M, O’Donnell JA et al (2012) NLRP1 inflammasome activation induces pyroptosis of hematopoietic progenitor cells. Immunity 37:1009–1023. doi:10.1016/j.immuni.2012.08.027
Jéru I, Duquesnoy P, Fernandes-Alnemri T, Cochet E, Yu JW, Lackmy-Port-Lis M et al (2008) Mutations in NALP12 cause hereditary periodic fever syndromes. Proc Natl Acad Sci U S A 105:1614–1619. doi:10.1073/pnas.0708616105
Borghini S, Tassi S, Chiesa S, Caroli F, Carta S, Caorsi R et al (2011) Clinical presentation and pathogenesis of cold-induced autoinflammatory disease in a family with recurrence of an NLRP12 mutation. Arthritis Rheum 63:830–839. doi:10.1002/art.30170
Jéru I, Le Borgne G, Cochet E, Hayrapetyan H, Duquesnoy P, Grateau G et al (2011) Identification and functional consequences of a recurrent NLRP12 missense mutation in periodic fever syndromes. Arthritis Rheum 63:1459–1464. doi:10.1002/art.30241
Vladimer GI, Weng D, Paquette SWM, Vanaja SK, Rathinam VAK, Aune MH et al (2012) The NLRP12 inflammasome recognizes Yersinia pestis. Immunity 37:96–107. doi:10.1016/j.immuni.2012.07.006
Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, Häfner R et al (2001) CARD15 mutations in Blau syndrome. Nat Genet 29:19–20. doi:10.1038/ng720
Rosé CD, Pans S, Casteels I, Anton J, Bader-Meunier B, Brissaud P et al (2015) Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes. Rheumatol Oxf Engl 54:1008–1016. doi:10.1093/rheumatology/keu437
Caso F, Costa L, Rigante D, Vitale A, Cimaz R, Lucherini OM et al (2014) Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis. Autoimmun Rev 13:1220–1229. doi:10.1016/j.autrev.2014.08.010
Kanazawa N, Okafuji I, Kambe N, Nishikomori R, Nakata-Hizume M, Nagai S et al (2005) Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. Blood 105:1195–1197. doi:10.1182/blood-2004-07-2972
Kobayashi K, Inohara N, Hernandez LD, Galán JE, Núñez G, Janeway CA et al (2002) RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 416:194–199. doi:10.1038/416194a
Magalhaes JG, Lee J, Geddes K, Rubino S, Philpott DJ, Girardin SE (2011) Essential role of Rip2 in the modulation of innate and adaptive immunity triggered by Nod1 and Nod2 ligands. Eur J Immunol 41:1445–1455. doi:10.1002/eji.201040827
Aróstegui JI, Arnal C, Merino R, Modesto C, Antonia Carballo M, Moreno P et al (2007) NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum 56:3805–3813. doi:10.1002/art.22966
Majeed HA, Kalaawi M, Mohanty D, Teebi AS, Tunjekar MF, al-Gharbawy F et al (1989) Congenital dyserythropoietic anemia and chronic recurrent multifocal osteomyelitis in three related children and the association with sweet syndrome in two siblings. J Pediatr 115:730–734
Ferguson PJ, Chen S, Tayeh MK, Ochoa L, Leal SM, Pelet A et al (2005) Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome). J Med Genet 42:551–557. doi:10.1136/jmg.2005.030759
Valdearcos M, Esquinas E, Meana C, Peña L, Gil-de-Gómez L, Balsinde J et al (2012) Lipin-2 reduces proinflammatory signaling induced by saturated fatty acids in macrophages. J Biol Chem 287:10894–10904. doi:10.1074/jbc.M112.342915
Herlin T, Fiirgaard B, Bjerre M, Kerndrup G, Hasle H, Bing X et al (2013) Efficacy of anti-IL-1 treatment in Majeed syndrome. Ann Rheum Dis 72:410–413. doi:10.1136/annrheumdis-2012-201818
Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A et al (2009) An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J med 360:2426–2437. doi:10.1056/NEJMoa0807865
Reddy S, Jia S, Geoffrey R, Lorier R, Suchi M, Broeckel U et al (2009) An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med 360:2438–2444. doi:10.1056/NEJMoa0809568
Jesus AA, Osman M, Silva CA, Kim PW, Pham T-H, Gadina M et al (2011) A novel mutation of IL1RN in the deficiency of interleukin-1 receptor antagonist syndrome: description of two unrelated cases from Brazil. Arthritis Rheum 63:4007–4017. doi:10.1002/art.30588
Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei X-Y, Fraitag S et al (2011) Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 365:620–628. doi:10.1056/NEJMoa1013068
Sugiura T, Kawaguchi Y, Harigai M, Terajima-Ichida H, Kitamura Y, Furuya T et al (2002) Association between adult-onset Still’s disease and interleukin-18 gene polymorphisms. Genes Immun 3:394–399. doi:10.1038/sj.gene.6363922
Kanazawa N, Nakamura T, Mikita N, Furukawa F (2013) Novel IL36RN mutation in a Japanese case of early onset generalized pustular psoriasis. J Dermatol 40:749–751. doi:10.1111/1346-8138.12227
Blumberg H, Dinh H, Trueblood ES, Pretorius J, Kugler D, Weng N et al (2007) Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med 204:2603–2614. doi:10.1084/jem.20070157
Martini A (2012) Systemic juvenile idiopathic arthritis. Autoimmun Rev 12:56–59. doi:10.1016/j.autrev.2012.07.022
Behrens EM, Beukelman T, Gallo L, Spangler J, Rosenkranz M, Arkachaisri T et al (2008) Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol 35:343–348
Feldman BM, Birdi N, Boone JE, Dent PB, Duffy CM, Ellsworth JE et al (1996) Seasonal onset of systemic-onset juvenile rheumatoid arthritis. J Pediatr 129:513–518
Modesto C, Antón J, Rodriguez B, Bou R, Arnal C, Ros J et al (2010) Incidence and prevalence of juvenile idiopathic arthritis in Catalonia (Spain). Scand J Rheumatol 39:472–479. doi:10.3109/03009741003742722
Schneider R, Laxer RM (1998) Systemic onset juvenile rheumatoid arthritis. Baillieres Clin Rheumatol 12:245–271
Pruunsild C, Uibo K, Liivamägi H, Tarraste S, Talvik T, Pelkonen P (2007) Incidence of juvenile idiopathic arthritis in children in Estonia: a prospective population-based study. Scand J Rheumatol 36:7–13. doi:10.1080/03009740601089259
Huemer C, Huemer M, Dorner T, Falger J, Schacherl H, Bernecker M et al (2001) Incidence of pediatric rheumatic diseases in a regional population in Austria. J Rheumatol 28:2116–2119
Kaipiainen-Seppänen O, Savolainen A (2001) Changes in the incidence of juvenile rheumatoid arthritis in Finland. Rheumatol Oxf Engl 40:928–932
Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201:1479–1486. doi:10.1084/jem.20050473
Jamilloux Y, Gerfaud-Valentin M, Martinon F, Belot A, Henry T, Sève P (2015) Pathogenesis of adult-onset Still’s disease: new insights from the juvenile counterpart. Immunol Res 61:53–62. doi:10.1007/s12026-014-8561-9
Ombrello MJ, Remmers EF, Tachmazidou I, Grom A, Foell D, Haas J-P et al (2015) HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proc Natl Acad Sci U S A 112:15970–15975. doi:10.1073/pnas.1520779112
Ombrello MJ, Arthur VL, Remmers EF, Hinks A, Tachmazidou I, Grom AA et al (2016) Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. Ann Rheum dis. doi:10.1136/annrheumdis-2016-210324
Wakil SM, Monies DM, Abouelhoda M, Al-Tassan N, Al-Dusery H, Naim EA et al (2015) Association of a mutation in LACC1 with a monogenic form of systemic juvenile idiopathic arthritis. Arthritis Rheumatol Hoboken NJ 67:288–295. doi:10.1002/art.38877
Cader MZ, Boroviak K, Zhang Q, Assadi G, Kempster SL, Sewell GW et al (2016) C13orf31 (FAMIN) is a central regulator of immunometabolic function. Nat Immunol 17:1046–1056. doi:10.1038/ni.3532
Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P (2014) Adult-onset Still’s disease. Autoimmun Rev 13:708–722. doi:10.1016/j.autrev.2014.01.058
Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, Durieu I et al (2014) Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore) 93:91–99. doi:10.1097/MD.0000000000000021
Pouchot J, Sampalis JS, Beaudet F, Carette S, Decary F, Salusinsky-Sternbach M et al (1991) Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore) 70:118–136
Ichiki H, Shishido M, Nishiyama S (1992) Two cases of adult onset of Still’s disease in the elderly. Nihon Ronen Igakkai Zasshi Jpn J Geriatr 29:960–964
Magadur-Joly G, Billaud E, Barrier JH, Pennec YL, Masson C, Renou P et al (1995) Epidemiology of adult Still’s disease: estimate of the incidence by a retrospective study in west France. Ann Rheum dis 54:587–590
Wakai K, Ohta A, Tamakoshi A, Ohno Y, Kawamura T, Aoki R et al (1997) Estimated prevalence and incidence of adult Still’s disease: findings by a nationwide epidemiological survey in Japan. J Epidemiol 7:221–225
Evensen KJ, Nossent HC (2006) Epidemiology and outcome of adult-onset Still’s disease in northern Norway. Scand J Rheumatol 35:48–51. doi:10.1080/03009740510026616
Chen D-Y, Lan J-L, Lin F-J, Hsieh T-Y (2005) Association of intercellular adhesion molecule-1 with clinical manifestations and interleukin-18 in patients with active, untreated adult-onset Still’s disease. Arthritis Rheum 53:320–327. doi:10.1002/art.21164
Narula N, Narula T, Abril A (2015) Seizing the clinical presentation in adult onset Still’s disease. An extensive literature review. Autoimmun rev 14:472–477. doi:10.1016/j.autrev.2015.01.007
Liozon E, Ly KH, Vidal-Cathala E, Fauchais A-L (2014) Adult-onset Still’s disease as a manifestation of malignancy: report of a patient with melanoma and literature review. Rev Médecine Interne Fondée par Société Natl Francaise Médecine Interne 35:60–64. doi:10.1016/j.revmed.2013.02.014
Jamilloux Y, Gerfaud-Valentin M, Henry T, Sève P (2015) Treatment of adult-onset Still’s disease: a review. Ther Clin Risk Manag 11:33–43. doi:10.2147/TCRM.S64951
Marshall GS, Edwards KM, Butler J, Lawton AR (1987) Syndrome of periodic fever, pharyngitis, and aphthous stomatitis. J Pediatr 110:43–46
Vigo G, Zulian F (2012) Periodic fevers with aphthous stomatitis, pharyngitis, and adenitis (PFAPA). Autoimmun Rev 12:52–55. doi:10.1016/j.autrev.2012.07.021
Rigante D, Vitale A, Natale MF, Lopalco G, Andreozzi L, Frediani B et al (2017) A comprehensive comparison between pediatric and adult patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome. Clin Rheumatol 36:463–468. doi:10.1007/s10067-016-3317-7
Feder HM, Salazar JC (2010) A clinical review of 105 patients with PFAPA (a periodic fever syndrome). Acta Paediatr Oslo nor 1992 99:178–184. doi:10.1111/j.1651-2227.2009.01554.x
Førsvoll J, Kristoffersen EK, Øymar K (2013) Incidence, clinical characteristics and outcome in Norwegian children with periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome; a population-based study. Acta Paediatr Oslo nor 1992 102:187–192. doi:10.1111/apa.12069
Hofer M, Pillet P, Cochard M-M, Berg S, Krol P, Kone-Paut I et al (2014) International periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis syndrome cohort: description of distinct phenotypes in 301 patients. Rheumatol Oxf Engl 53:1125–1129. doi:10.1093/rheumatology/ket460
Theodoropoulou K, Vanoni F, Hofer M (2016) Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome: a review of the pathogenesis. Curr Rheumatol Rep 18:18. doi:10.1007/s11926-016-0567-y
Cheung MS, Theodoropoulou K, Lugrin J, Martinon F, Busso N, Hofer M (2017) Periodic fever with aphthous stomatitis, pharyngitis, and cervical adenitis syndrome is associated with a CARD8 variant unable to bind the NLRP3 inflammasome. J Immunol 198:2063–2069. doi:10.4049/jimmunol.1600760
Stojanov S, Lapidus S, Chitkara P, Feder H, Salazar JC, Fleisher TA et al (2011) Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade. Proc Natl Acad Sci U S A 108:7148–7153. doi:10.1073/pnas.1103681108
Cochard M, Clet J, Le L, Pillet P, Onrubia X, Guéron T et al (2010) PFAPA syndrome is not a sporadic disease. Rheumatol Oxf Engl 49:1984–1987. doi:10.1093/rheumatology/keq187
Perko D, Debeljak M, Toplak N, Avčin T (2015) Clinical features and genetic background of the periodic fever syndrome with aphthous stomatitis, pharyngitis, and adenitis: a single center longitudinal study of 81 patients. Mediat Inflamm 2015:293417. doi:10.1155/2015/293417
Ter Haar N, Lachmann H, Özen S, Woo P, Uziel Y, Modesto C et al (2013) Treatment of autoinflammatory diseases: results from the Eurofever registry and a literature review. Ann Rheum Dis 72:678–685. doi:10.1136/annrheumdis-2011-201268
Burton MJ, Pollard AJ, Ramsden JD, Chong LY, Venekamp RP (2014) Tonsillectomy for periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome (PFAPA). Cochrane Database Syst Rev 11:CD008669. doi:10.1002/14651858.CD008669.pub2
Vanoni F, Theodoropoulou K, Hofer M (2016) PFAPA syndrome: a review on treatment and outcome. Pediatr Rheumatol Online J 14. doi:10.1186/s12969-016-0101-9
Schnitzler L, Schubert B, Verret JL, Simon L, Alquier P (1976) Cutaneous manifestations in disseminated intravascular coagulation syndrome. Ann Dermatol Syphiligr (Paris) 103:124–134
Lipsker D (2010) The Schnitzler syndrome. Orphanet J Rare Dis 5:38. doi:10.1186/1750-1172-5-38
Simon A, Asli B, Braun-Falco M, De Koning H, Fermand J-P, Grattan C et al (2013) Schnitzler’s syndrome: diagnosis, treatment, and follow-up. Allergy 68:562–568. doi:10.1111/all.12129
de Koning HD, Schalkwijk J, van der Meer JWM, Simon A (2011) Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome. J Allergy Clin Immunol 128:1352–1354. doi:10.1016/j.jaci.2011.05.023
de Koning HD, Schalkwijk J, van der Ven-Jongekrijg J, Stoffels M, van der Meer JWM, Simon A (2013) Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler’s syndrome. Ann Rheum Dis 72:1634–1638. doi:10.1136/annrheumdis-2012-202192
de Koning HD, van Gijn ME, Stoffels M, Jongekrijg J, Zeeuwen PLJM, Elferink MG et al (2015) Myeloid lineage-restricted somatic mosaicism of NLRP3 mutations in patients with variant Schnitzler syndrome. J Allergy Clin Immunol 135:561–564. doi:10.1016/j.jaci.2014.07.050
Zhou Q, Aksentijevich I, Wood GM, Walts AD, Hoffmann P, Remmers EF et al (2015) Brief report: cryopyrin-associated periodic syndrome caused by a myeloid-restricted somatic NLRP3 mutation. Arthritis Rheumatol Hoboken NJ 67:2482–2486. doi:10.1002/art.39190
Crow YJ (2011) Type I interferonopathies: a novel set of inborn errors of immunity. Ann N Y Acad Sci 1238:91–98. doi:10.1111/j.1749-6632.2011.06220.x
Rodero MP, Crow YJ (2016) Type I interferon-mediated monogenic autoinflammation: the type I interferonopathies, a conceptual overview. J Exp med 213:2527–2538. doi:10.1084/jem.20161596
Picard C, Mathieu A-L, Hasan U, Henry T, Jamilloux Y, Walzer T et al (2015) Inherited anomalies of innate immune receptors in pediatric-onset inflammatory diseases. Autoimmun Rev 14:1147–1153. doi:10.1016/j.autrev.2015.08.002
Picard C, Belot A (2016) Type I interferonopathies. Literature review. Rev Med Interne. doi:10.1016/j.revmed.2016.08.016
Atianand MK, Fitzgerald KA (2013) Molecular basis of DNA recognition in the immune system. J Immunol Baltim md 1950 190:1911–1918. doi:10.4049/jimmunol.1203162
Chen Q, Sun L, Chen ZJ (2016) Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat Immunol 17:1142–1149. doi:10.1038/ni.3558
Frémond M-L, Rodero MP, Jeremiah N, Belot A, Jeziorski E, Duffy D et al (2016) Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. J Allergy Clin Immunol 138:1752–1755. doi:10.1016/j.jaci.2016.07.015
Aicardi J, Goutières F (1984) A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis. Ann Neurol 15:49–54. doi:10.1002/ana.410150109
Rice GI, del Toro Duany Y, Jenkinson EM, Forte GMA, Anderson BH, Ariaudo G et al (2014) Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat Genet 46:503–509. doi:10.1038/ng.2933
Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Montealegre Sanchez GA et al (2014) Activated STING in a vascular and pulmonary syndrome. N Engl J Med 371:507–518. doi:10.1056/NEJMoa1312625
Jeremiah N, Neven B, Gentili M, Callebaut I, Maschalidi S, Stolzenberg M-C et al (2014) Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J Clin Invest 124:5516–5520. doi:10.1172/JCI79100
Crow YJ, Casanova J-L (2014) STING-associated vasculopathy with onset in infancy—a new interferonopathy. N Engl J Med 371:568–571. doi:10.1056/NEJMe1407246
Agarwal AK, Xing C, DeMartino GN, Mizrachi D, Hernandez MD, Sousa AB et al (2010) PSMB8 encoding the β5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. Am J Hum Genet 87:866–872. doi:10.1016/j.ajhg.2010.10.031
Arima K, Kinoshita A, Mishima H, Kanazawa N, Kaneko T, Mizushima T et al (2011) Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc Natl Acad Sci U S A 108:14914–14919. doi:10.1073/pnas.1106015108
Kitamura A, Maekawa Y, Uehara H, Izumi K, Kawachi I, Nishizawa M et al (2011) A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans. J Clin Invest 121:4150–4160. doi:10.1172/JCI58414
Brehm A, Liu Y, Sheikh A, Marrero B, Omoyinmi E, Zhou Q et al (2015) Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. J Clin Invest 125:4196–4211. doi:10.1172/JCI81260
Murarasu A, Dodé C, Sarrabay G, Klein I, Papo T, Sacré K (2017) Digenic MEFV/TNFRSF1A autoinflammatory syndrome with relapsing aseptic neutrophilic meningitis and chronic myelitis. Clin Exp Rheumatol
Stoffels M, Kastner DL (2016) Old dogs, new tricks: monogenic autoinflammatory disease unleashed. Annu Rev Genomics Hum Genet 17:245–272. doi:10.1146/annurev-genom-090413-025334
McDermott A, Jacks J, Kessler M, Emanuel PD, Gao L (2015) Proteasome-associated autoinflammatory syndromes: advances in pathogeneses, clinical presentations, diagnosis, and management. Int J Dermatol 54:121–129. doi:10.1111/ijd.12695
Jang M-A, Kim EK, Now H, Nguyen NTH, Kim W-J, Yoo J-Y et al (2015) Mutations in DDX58, which encodes RIG-I, cause atypical Singleton-Merten syndrome. Am J Hum Genet 96:266–274. doi:10.1016/j.ajhg.2014.11.019
Briggs TA, Rice GI, Daly S, Urquhart J, Gornall H, Bader-Meunier B et al (2011) Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat Genet 43:127–131. doi:10.1038/ng.748
Lausch E, Janecke A, Bros M, Trojandt S, Alanay Y, De Laet C et al (2011) Genetic deficiency of tartrate-resistant acid phosphatase associated with skeletal dysplasia, cerebral calcifications and autoimmunity. Nat Genet 43:132–137. doi:10.1038/ng.749
Briggs TA, Rice GI, Adib N, Ades L, Barete S, Baskar K et al (2016) Spondyloenchondrodysplasia due to mutations in ACP5: a comprehensive survey. J Clin Immunol 36:220–234. doi:10.1007/s10875-016-0252-y
Starokadomskyy P, Gemelli T, Rios JJ, Xing C, Wang RC, Li H et al (2016) DNA polymerase-α regulates the activation of type I interferons through cytosolic RNA:DNA synthesis. Nat Immunol 17:495–504. doi:10.1038/ni.3409
Fernandez-Guarino M, Torrelo A, Fernandez-Lorente M, Fraile G, García-Sagredo JM, Jaén P (2008) X-linked reticulate pigmentary disorder: report of a new family. Eur J Dermatol EJD 18:102–103. doi:10.1684/ejd.2007.0336
Bogunovic D, Byun M, Durfee LA, Abhyankar A, Sanal O, Mansouri D et al (2012) Mycobacterial disease and impaired IFN-γ immunity in humans with inherited ISG15 deficiency. Science 337:1684–1688. doi:10.1126/science.1224026
Zhang X, Bogunovic D, Payelle-Brogard B, Francois-Newton V, Speer SD, Yuan C et al (2015) Human intracellular ISG15 prevents interferon-α/β over-amplification and auto-inflammation. Nature 517:89–93. doi:10.1038/nature13801
Meuwissen MEC, Schot R, Buta S, Oudesluijs G, Tinschert S, Speer SD et al (2016) Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome. J Exp Med 213:1163–1174. doi:10.1084/jem.20151529
Bulua AC, Mogul DB, Aksentijevich I, Singh H, He DY, Muenz LR et al (2012) Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum 64:908–913. doi:10.1002/art.33416
Rebelo SL, Bainbridge SE, Amel-Kashipaz MR, Radford PM, Powell RJ, Todd I et al (2006) Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function. Arthritis Rheum 54:2674–2687. doi:10.1002/art.21964
Hull KM, Drewe E, Aksentijevich I, Singh HK, Wong K, McDermott EM et al (2002) The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 81:349–368
Lainka E, Neudorf U, Lohse P, Timmann C, Stojanov S, Huss K et al (2009) Incidence of TNFRSF1A mutations in German children: epidemiological, clinical and genetic characteristics. Rheumatol Oxf Engl 48:987–991. doi:10.1093/rheumatology/kep140
Gattorno M, Pelagatti MA, Meini A, Obici L, Barcellona R, Federici S et al (2008) Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 58:1516–1520. doi:10.1002/art.23475
Sacré K, Brihaye B, Lidove O, Papo T, Pocidalo M-A, Cuisset L et al (2008) Dramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapy. J Rheumatol 35:357–358
Grimwood C, Despert V, Jeru I, Hentgen V (2015) On-demand treatment with anakinra: a treatment option for selected TRAPS patients. Rheumatol Oxf Engl 54:1749–1751. doi:10.1093/rheumatology/kev111
Bulua AC, Simon A, Maddipati R, Pelletier M, Park H, Kim K-Y et al (2011) Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med 208:519–533. doi:10.1084/jem.20102049
Borghini S, Ferrera D, Prigione I, Fiore M, Ferraris C, Mirisola V et al (2016) Gene expression profile in TNF receptor-associated periodic syndrome reveals constitutively enhanced pathways and new players in the underlying inflammation. Clin Exp Rheumatol 34:S121–S128
Jéru I, Cochet E, Duquesnoy P, Hentgen V, Copin B, Mitjavila-Garcia MT et al (2014) Brief report: involvement of TNFRSF11A molecular defects in autoinflammatory disorders. Arthritis Rheumatol Hoboken NJ 66:2621–2627. doi:10.1002/art.38727
Blaydon DC, Biancheri P, Di W-L, Plagnol V, Cabral RM, Brooke MA et al (2011) Inflammatory skin and bowel disease linked to ADAM17 deletion. N Engl J med 365:1502–1508. doi:10.1056/NEJMoa1100721
Hu H, Sun S-C (2016) Ubiquitin signaling in immune responses. Cell res 26:457–483. doi:10.1038/cr.2016.40
Cohen P (2014) Immune diseases caused by mutations in kinases and components of the ubiquitin system. Nat Immunol 15:521–529. doi:10.1038/ni.2892
Zhou Q, Wang H, Schwartz DM, Stoffels M, Park YH, Zhang Y et al (2016) Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat Genet 48:67–73. doi:10.1038/ng.3459
Shigemura T, Kaneko N, Kobayashi N, Kobayashi K, Takeuchi Y, Nakano N et al (2016) Novel heterozygous C243Y A20/TNFAIP3 gene mutation is responsible for chronic inflammation in autosomal-dominant Behçet’s disease. RMD Open 2:e000223. doi:10.1136/rmdopen-2015-000223
Ohnishi H, Kawamoto N, Seishima M, Ohara O, Fukao T (2017) A Japanese family case with juvenile onset Behçet’s disease caused by TNFAIP3 mutation. Allergol Int Off J Jpn Soc Allergol 66:146–148. doi:10.1016/j.alit.2016.06.006
Wertz IE, O’Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S et al (2004) De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 430:694–699. doi:10.1038/nature02794
Vande Walle L, Van Opdenbosch N, Jacques P, Fossoul A, Verheugen E, Vogel P et al (2014) Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis. Nature 512:69–73. doi:10.1038/nature13322
Duong BH, Onizawa M, Oses-Prieto JA, Advincula R, Burlingame A, Malynn BA et al (2015) A20 restricts ubiquitination of pro-interleukin-1β protein complexes and suppresses NLRP3 inflammasome activity. Immunity 42:55–67. doi:10.1016/j.immuni.2014.12.031
Shimizu Y, Taraborrelli L, Walczak H (2015) Linear ubiquitination in immunity. Immunol Rev 266:190–207. doi:10.1111/imr.12309
Fiil BK, Gyrd-Hansen M (2014) Met1-linked ubiquitination in immune signalling. FEBS J 281:4337–4350. doi:10.1111/febs.12944
Elliott PR, Komander D (2016) Regulation of Met1-linked polyubiquitin signalling by the deubiquitinase OTULIN. FEBS J 283:39–53. doi:10.1111/febs.13547
Zhou Q, Yu X, Demirkaya E, Deuitch N, Stone D, Tsai WL et al (2016) Biallelic hypomorphic mutations in a linear deubiquitinase define otulipenia, an early-onset autoinflammatory disease. Proc Natl Acad Sci U S A 113:10127–10132. doi:10.1073/pnas.1612594113
Boisson B, Laplantine E, Prando C, Giliani S, Israelsson E, Xu Z et al (2012) Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency. Nat Immunol 13:1178–1186. doi:10.1038/ni.2457
Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV et al (2014) Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 370:911–920. doi:10.1056/NEJMoa1307361
Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padeh S et al (2014) Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 370:921–931. doi:10.1056/NEJMoa1307362
Ben-Ami T, Revel-Vilk S, Brooks R, Shaag A, Hershfield MS, Kelly SJ et al (2016) Extending the clinical phenotype of adenosine deaminase 2 deficiency. J Pediatr 177:316–320. doi:10.1016/j.jpeds.2016.06.058
Zavialov AV, Gracia E, Glaichenhaus N, Franco R, Zavialov AV, Lauvau G (2010) Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. J Leukoc Biol 88:279–290. doi:10.1189/jlb.1109764
Ombrello MJ, Remmers EF, Sun G, Freeman AF, Datta S, Torabi-Parizi P et al (2012) Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med 366:330–338. doi:10.1056/NEJMoa1102140
Zhou Q, Lee G-S, Brady J, Datta S, Katan M, Sheikh A et al (2012) A hypermorphic missense mutation in PLCG2, encoding phospholipase Cγ2, causes a dominantly inherited autoinflammatory disease with immunodeficiency. Am J Hum Genet 91:713–720. doi:10.1016/j.ajhg.2012.08.006
Chae JJ, Park YH, Park C, Hwang I-Y, Hoffmann P, Kehrl JH et al (2015) Connecting two pathways through Ca 2+ signaling: NLRP3 inflammasome activation induced by a hypermorphic PLCG2 mutation. Arthritis Rheumatol Hoboken NJ 67:563–567. doi:10.1002/art.38961
Wiseman DH, May A, Jolles S, Connor P, Powell C, Heeney MM et al (2013) A novel syndrome of congenital sideroblastic anemia, B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD). Blood 122:112–123. doi:10.1182/blood-2012-08-439083
Chakraborty PK, Schmitz-Abe K, Kennedy EK, Mamady H, Naas T, Durie D et al (2014) Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD). Blood 124:2867–2871. doi:10.1182/blood-2014-08-591370
Sasarman F, Thiffault I, Weraarpachai W, Salomon S, Maftei C, Gauthier J et al (2015) The 3′ addition of CCA to mitochondrial tRNASer(AGY) is specifically impaired in patients with mutations in the tRNA nucleotidyl transferase TRNT1. Hum Mol Genet 24:2841–2847. doi:10.1093/hmg/ddv044
Kaustio M, Haapaniemi E, Göös H, Hautala T, Park G, Syrjänen J et al (2017) Damaging heterozygous mutations in NFKB1 lead to diverse immunological phenotypes. J Allergy Clin Immunol. doi:10.1016/j.jaci.2016.10.054
Schipp C, Nabhani S, Bienemann K, Simanovsky N, Kfir-Erenfeld S, Assayag-Asherie N et al (2016) Specific antibody deficiency and autoinflammatory disease extend the clinical and immunological spectrum of heterozygous NFKB1 loss-of-function mutations in humans. Haematologica 101:e392–e396. doi:10.3324/haematol.2016.145136
Molho-Pessach V, Lerer I, Abeliovich D, Agha Z, Abu Libdeh A, Broshtilova V et al (2008) The H syndrome is caused by mutations in the nucleoside transporter hENT3. Am J Hum Genet 83:529–534. doi:10.1016/j.ajhg.2008.09.013
Melki I, Lambot K, Jonard L, Couloigner V, Quartier P, Neven B et al (2013) Mutation in the SLC29A3 gene: a new cause of a monogenic, autoinflammatory condition. Pediatrics 131:e1308–e1313. doi:10.1542/peds.2012-2255
Jordan CT, Cao L, Roberson EDO, Pierson KC, Yang C-F, Joyce CE et al (2012) PSORS2 is due to mutations in CARD14. Am J hum Genet 90:784–795. doi:10.1016/j.ajhg.2012.03.012
Fuchs-Telem D, Sarig O, van Steensel MAM, Isakov O, Israeli S, Nousbeck J et al (2012) Familial pityriasis rubra pilaris is caused by mutations in CARD14. Am J Hum Genet 91:163–170. doi:10.1016/j.ajhg.2012.05.010
Eytan O, Sarig O, Sprecher E, van Steensel MA (2014) Clinical response to ustekinumab in familial pityriasis rubra pilaris caused by a novel mutation in CARD14. Br J Dermatol 171:420–422. doi:10.1111/bjd.12952
Setta-Kaffetzi N, Simpson MA, Navarini AA, Patel VM, Lu H-C, Allen MH et al (2014) AP1S3 mutations are associated with pustular psoriasis and impaired toll-like receptor 3 trafficking. Am J hum Genet 94:790–797. doi:10.1016/j.ajhg.2014.04.005
Mahil SK, Twelves S, Farkas K, Setta-Kaffetzi N, Burden AD, Gach JE et al (2016) AP1S3 mutations cause skin autoinflammation by disrupting keratinocyte autophagy and up-regulating IL-36 production. J Invest Dermatol 136:2251–2259. doi:10.1016/j.jid.2016.06.618
Gattorno M, Sormani MP, D’Osualdo A, Pelagatti MA, Caroli F, Federici S et al (2008) A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. Arthritis Rheum 58:1823–1832. doi:10.1002/art.23474
Federici S, Gattorno M (2014) A practical approach to the diagnosis of autoinflammatory diseases in childhood. Best Pract Res Clin Rheumatol 28:263–276. doi:10.1016/j.berh.2014.05.005
Moghaddas F, Masters SL (2015) Monogenic autoinflammatory diseases: Cytokinopathies. Cytokine 74:237–246. doi:10.1016/j.cyto.2015.02.012
Acknowledgments
This work was supported by the Société Nationale Française de Médecine Interne (SNFMI), the Foundation for the Development of Internal Medicine in Europe, and a « poste d’accueil INSERM » (to Y.J.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Jamilloux, Y., Belot, A., Magnotti, F. et al. Geoepidemiology and Immunologic Features of Autoinflammatory Diseases: a Comprehensive Review. Clinic Rev Allerg Immunol 54, 454–479 (2018). https://doi.org/10.1007/s12016-017-8613-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-017-8613-8